Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06174220 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy

Study acronym: TaRGET
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites revised (17)
    • Collaborators revised (5)
    v7
  2. Site details revised at 5 of 17 sitesv6
  3. Trial status: Not Yet Recruiting to Recruitingv5 Show 4 more changesShow less
    • Primary completion date: Feb 1, 2026 to Feb 1, 2027
    • Start date changed from estimate of Oct 1, 2024 to Mar 21, 2025
    • Study sites: 19 to 17
    • Study completion date: Jul 1, 2026 to Jul 1, 2027
  4. Start date: Apr 1, 2024 to Oct 1, 2024
    • Eligibility criteria expanded, about 16 words
    • Study sites revised (19)
    v4
  5. Start date: Feb 1, 2024 to Apr 1, 2024
    • Study sites: 18 to 19
    • Collaborators: 4 to 5
    v3
  6. Collaborators: 2 to 4v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The TaRGET study is a multi-centre, prospective, randomized, double-blind, placebo-controlled trial designed to evaluate the potential therapeutic efficacy of tideglusib, a glycogen synthase kinase-3 β inhibitor, in genotype positive arrhythmogenic cardiomyopathy.
Trial Details
NCT Number NCT06174220
Lead Sponsor Hamilton Health Sciences Corporation
Collaborators: Canadian Institutes of Health Research (CIHR), Canadian SADS, AMO Pharma Limited, Hearts in Rhythm Organization (HiRO), Population Health Research Institute
Conditions
(from sponsor)		 Arrhythmogenic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy
Related terms Arrhythmias, Cardiac, Arrhythmogenic Right Ventricular Dysplasia, Death, Sudden, Cardiac
Enrollment 120 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov